首页> 美国卫生研究院文献>British Journal of Cancer >Resistance of human glioma to adriamycin in vitro: the role of membrane transport and its circumvention with verapamil.
【2h】

Resistance of human glioma to adriamycin in vitro: the role of membrane transport and its circumvention with verapamil.

机译:人神经胶质瘤对阿霉素的体外耐药性:膜转运的作用及其与维拉帕米的规避作用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We have investigated the mechanism of resistance to adriamycin (ADR) of 3 human glioma cell lines in culture. The cell lines had different inherent sensitivities to ADR. Verapamil increased the ADR sensitivities of the 2 most resistant cell lines (G-UVW and G-CCM) by up to 5-fold. This effect was not seen in a sensitive cell line (G-MCF). Although the accumulation of ADR in the 3 cell lines was not related to inherent sensitivity, energy deprivation or the addition of verapamil produced an increase (up to 46%) in net uptake for both G-UVW and G-CCM, but not for G-MCF. For G-UVW the ADR efflux data were consistent with an energy-dependent ADR efflux mechanism which could be inhibited by verapamil. A similar mechanism was not found for G-CCM. In this cell line verapamil may act by increasing intracellular ADR binding. These data indicate that, while inherent resistance to ADR may be multifactorial, one possible mechanism of resistance in human glioma may involve changes in drug accumulation and/or binding as has been seen in animals models. A potential clinical role for verapamil in overcoming drug resistance in human solid tumours is also indicated.
机译:我们已经研究了文化中的三种人类神经胶质瘤细胞系对阿霉素(ADR)的抗性机制。细胞系对ADR具有不同的固有敏感性。维拉帕米将两种耐药性最高的细胞系(G-UVW和G-CCM)的ADR敏感性提高了5倍。在敏感细胞系(G-MCF)中未发现此效果。尽管3种细胞系中ADR的积累与内在敏感性无关,但能量缺乏或维拉帕米的添加对G-UVW和G-CCM的净摄取均增加(高达46%),但对G-UVW和G-CCM均不增加。 -MCF。对于G-UVW,ADR外排数据与能量依赖的ADR外排机制一致,而维拉帕米可以抑制该机制。对于G-CCM,没有发现类似的机制。在这种细胞系中,维拉帕米可能通过增加细胞内ADR结合发挥作用。这些数据表明,尽管对ADR的固有抗性可能是多因素的,但人类胶质瘤抗性的一种可能机制可能涉及药物蓄积和/或结合的变化,如在动物模型中所见。还显示了维拉帕米在克服人类实体瘤中的耐药性方面的潜在临床作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号